

CD13D/CD3E & CD19 Research Grade Surovatamig

Catalog No.	DHD10834A DHD10834B	Quantity:	100 µg 1.0 mg
Alternate Names:	CD3d, CD3e, CD19, AZD-0486, AZD0486, TNB-486, TNB486, CAS: 2892667-02-4, Bispecific		
Description:	Surovatamig is a human/humanized CD19 x CD3 bispecific T-cell engager (BiTE) monoclonal antibody in studies for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.		
UniProt ID (target):	P04234/P07766 & P15391		
Specificity:	Human CD3d/CD3e and CD19		
Concentration:	1.0 mg/ml, lot specific		
Source:	Mammalian cells		
Isotype:	Human/Humanized half-IgG4-kappa/VH-IgG4 (h-CH2-CH3)		
Formulation:	0.01M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography from cell culture supernatant		
Applications:	Functional studies		
INN:	Surovatamig		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

